search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

[Second primary tumors in patients treated at an early age for Hodgkin's disease; consequences for the follow-up].

B M Aleman ,
W J Klokman ,
F E van Leeuwen

Abstract

As curative treatment is now available for a substantial group of cancer patients, it is increasingly important to evaluate how late complications of treatment affect their long-term survival. Two recent publications summarize the second malignancies in survivors of Hodgkin's disease treated during adolescence or young adulthood. After more than 20 years' follow-up, the risk of solid tumours is still much greater in survivors of Hodgkin's disease than in the population at large. Age at treatment has a major effect on the occurrence of second malignancy. Reassuringly, the increased risk of solid tumours in patients who were less than 20 years of age seems to decrease as these patients grow older. The data of these studies suggest that chemotherapy may increase the risk of solid tumours from radiotherapy. Special alertness to symptoms of second malignancies is advised during follow-up after treatment for Hodgkin's disease, especially in patients treated below the age of 20.

More about this publication

Nederlands tijdschrift voor geneeskunde

Volume 144
Issue nr. 32
Pages 1517-20
Publication date 05-08-2000

Full text links

Publisher website (DOI) 10949633
Europe PubMed Central 10949633

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.